Antinuclear antibodies measured by enzyme immunoassay in patients with systemic lupus erythematosus: relation to disease activity
Antinuclear antibodies measured by enzyme immunoassay in patients with systemic lupus erythematosus: relation to disease activity
复制标题
DOI：
10.1007/s00296-007-0324-7
复制
发表时间：
2007-08-01
影响因子：
4
通讯作者：
Mader, Reuven
中科院分区：
文献类型：
--
作者：
Paz, Ehud;Adawi, Muhammed;Mader, Reuven
目的评价血清抗核抗体酶免疫测定（ANA-EIA）水平与系统性红斑狼疮疾病活动度的相关性。与免疫荧光法（ANA-IIF）测定抗核抗体进行比较，重新检验该方法的性能。对71例SLE患者的85份血清进行了检测。收集人口统计学、临床、实验室和SLEDAI状态。分别以1:40和1:160的稀释度检测血清中ANA-EIA和ANA-IIF。将血清ANA-EIA水平与SLEDAI总分及其各组成部分进行比较。SLEDAI评分>= 6被认为具有临床意义。51名健康志愿者的血清作为对照。SLEDAI评分为b> = 6的患者血清ANA-EIA水平显著高于SLEDAI评分< 6的患者组（P = 0.004）。血清ANA-EIA高水平与DS-DNA抗体升高（P < 0.001）、低C-3或C-4水平（P < 0.001）、脓尿（P < 0.011）、关节炎（P = 0.019）和新发皮疹（P = 0.019）显著相关。IIF检测阳性的患者ANA-EIA水平明显高于检测阴性的患者。较高的血清ANA-EIA水平与SLE患者的临床显著疾病活动性相关。较高的血清ANA-EIA水平也与SLEDAI的一些单项指标相关。结果也重申了ANA-EIA检测在SLE患者中的有效性。为了验证血清ANA-EIA水平可能反映疾病活动波动的假设，需要进一步的纵向研究。
To evaluate the correlation between measurements of antinuclear antibodies serum levels by enzyme immunoassay (ANA-EIA), and the degree of systemic lupus erythematosus disease activity. To retest the performance of the test compared to measurement of antinuclear antibodies by immunofluorescence (ANA-IIF). Eighty-five sera from 71 patients with SLE were tested. Demographic, clinical, laboratory, and SLEDAI status were collected. The sera were tested for ANA-EIA and by ANA-IIF at 1:40 and 1:160 dilutions. Serum levels of ANA-EIA were compared to the overall SLEDAI score and to each of its components. A SLEDAI score of >= 6 was considered clinically significant. The sera of fifty-one healthy volunteers served as controls. Serum levels of ANA-EIA were significantly higher in patients with a SLEDAI score of >= 6 compared to the group of patients with a SLEDAI score of < 6 (P = 0.004). High serum levels of ANA-EIA correlated significantly with elevated anti DS-DNA antibodies (P < 0.001), low C-3 or C-4 levels (P < 0.001), pyuria (P < 0.011), arthritis (P = 0.019), and new rash (P = 0.019). Levels of ANA-EIA were significantly higher in patients tested positive by IIF compared to those who tested negative. Higher serum levels of ANA-EIA correlated with clinically significant disease activity in patients with SLE. Higher serum levels of ANA-EIA also correlated with some single items of the SLEDAI. The results also reiterated the validity of ANA-EIA testing in patients with SLE. Further longitudinal studies are needed in order to test the hypothesis that serum ANA-EIA levels might reflect fluctuations in disease activity.